IPCALAB
Large CapIPCA Laboratories Limited
Pharma
Ipca Laboratories Limited is an Indian pharmaceutical company with a presence in domestic formulations, export formulations, and API manufacturing. It has a significant domestic market share and is expanding its global generic and biosimilar footprint, including through its Unichem acquisition.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is supportive, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Good · 70/100Rev +6% YoY · PAT +380% YoY · margin expansion · operating leverage
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹2,388 Cr | +6.3% | -0.2% |
| EBITDA | ₹484 Cr | +12.8% | -9.2% |
| Operating margin | 20.0% | +100 bps | -200 bps |
| PAT | ₹307 Cr | +379.7% | -15.7% |
| PAT margin | 12.9% | +1001 bps | -236 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Where growth can come from, and what can break the case
Q3 FY26 consolidated revenue grew 6.5% YoY to INR 2,245 crores, driven by strong domestic (12%) and export (17%) formulations growth. Consolidated EBITDA margin improved significantly to 22.5% from 19.87% YoY, despite flat API business and Unichem's US market share challenges.
Ipca's core domestic and export formulations businesses continue to outperform, driving robust revenue growth and margin expansion. While Unichem faces near-term pressure from US market share loss, management's focus on new launches and European expansion, alongside Ipca's own US portfolio build-out and biosimilar pipeline, supports future growth.
Domestic Formulations
Domestic business grew 12% in Q3, outpacing IPM. Pain segment (over 50% of business) grew 13%, cardiovascular 16%, diabetes 14%, CNS 19%, derma 22%, neurology 17%.
Export Branded Formulations
Promotional branded business is stable, expected to grow 10-12% over longer term. West Africa grew 69% in Q3, Latin America 20%, Middle East/Africa 27%, East Asia 36%.
US Generics (Ipca Portfolio)
5 Ipca molecules commercialized in US, with 25%+ market share for backward-integrated products. Another 5-7 molecules to be commercialized in next 12-15 months.
Biosimilars
5 biosimilar candidates with technology transfer initiated for two products. Targeting all global markets, including US, Europe, and UK.
Solar Project
A solar project is currently going on to use more green energy, with a capital outlook of almost around INR 50 crores.
Unichem Plant Utilization
Unichem has a lot of capacity in their manufacturing plant; once that starts getting utilized, their margins will automatically improve.
Product Mix Improvement
Overall gross margin is a function of top line growth, with higher-margin domestic and branded businesses growing faster, leading to improved material cost-to-sales ratio.
Stable Material Prices
Material prices are by and large stable, with slightly upward movement but not very significant.
UK Generic Market Recovery
Last 1 month, a sharp recovery in prices (as high as 30-40%) has been seen in the fiercely competitive UK generic market.
Unichem US Market Share Loss
Unichem lost certain high-volume businesses in the US due to increased competition and price reduction, impacting margins. This decline started in Q2 and may continue for 1-2 more quarters.
Institutional Business Uncertainties
Uncertainties in the institutional business are a factor in the overall generic business growth outlook.
Antimalarial Decline
Antimalarial business declined by almost around 21% in Q3, impacting overall domestic API business.
Competition & Pricing Pressure (US Generics)
Unichem faced market share loss in key US products due to increased competition and price reduction, impacting profitability.
Institutional Business Volatility
Uncertainties in the institutional business could lead to lower growth in generic formulations.
Currency Fluctuations
Promotional branded business can be impacted when currency goes for a toss in the market.
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Most key financial metrics (revenue, EBITDA margin, segment growth) are explicitly compared to the prior year's quarter (Q3 FY25) or 9-month period, indicating a focus on annual performance trends.
Domestic Formulations Growth
Domestic business for Q3 FY26 delivered growth of around 12%. Ipca outpaced IPM (10.6% vs 8.9%). Acute segment grew 8.4% vs IPM 6.9%; Chronic segment grew 15% vs IPM 12%.
Export Formulations Growth
Export formulation business in Q3 delivered growth of around 17%. For 9 months, it grew 6% from INR 1,395 crores to INR 1,477 crores.
API Business Growth
API business during Q3 FY26 was flat at around INR 317 crores. For 9 months, it grew 14% to around INR 1,051 crores from INR 924 crores.
Consolidated EBITDA Margin
Consolidated EBITDA margin for Q3 FY26 is at around 22.5% as against 19.87% in Q3 FY25, an improvement of around 2.28%.
Unichem Growth & Margin Targets
Management aims for Unichem's overall top line to grow 8-10% and EBITDA margin to reach 15% in 2-3 years, gradually improving to 20% with European filings and registrations.
Ipca Ex-Unichem Growth & Margin Outlook
Overall company growth (ex-Unichem) is expected to be around 10-11%, with EBITDA margin improving by 1.5% annually, provided top line growth is 10-12%.
Biosimilar Commercialization
Technology transfer for two biosimilar products has started, with manufacturing expected to commence shortly, targeting global markets.
Domestic Market Outperformance
Company expects to continue beating the domestic market, driven by growth in pain, cardiovascular, diabetes, CNS, derma, and neurology segments.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Unichem US Market Share Recovery | Market share lost in 1-2 molecules, impacting Q2 and Q3, expected to continue for 1-2 more quarters. | Evidence of regaining market share in existing molecules and successful commercialization of new launches to stabilize and grow Unichem's US business. |
| Unichem European Filings & Registrations | Filings are happening, few already filed. Registration takes 1-2 years. | Progress on European registrations and subsequent commercialization of products to drive Unichem's top line and margin improvement. |
| Ipca US Product Launches | 5 Ipca molecules commercialized, 5-7 more expected in 12-15 months. 4 US filings made this year, 5-6 annually. | Timely approvals and successful commercialization of Ipca's backward-integrated portfolio in the US market to contribute to consolidated growth. |
| Consolidated EBITDA Margin Trajectory | Q3 FY26 consolidated EBITDA margin at 22.5%, up 2.28% YoY. Management expects 1.5% annual improvement for core business. | Sustained margin expansion driven by favorable product mix, higher utilization, and cost efficiencies, especially as Unichem's margins improve. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
55NeutralSMA20 +6.3% / mo · near 52W high
Technical chart
IPCALABweekly · 1Y+19.4%Technical trend read
Bullish setupTrend is constructive — long-term trend unclear. RSI 58.
- SMA20 rising (~6.0% over last month) — short-term momentum positive.
- RSI(14) at 58 — rising, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- Within 3% of 52-week high — testing resistance.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
WATCHLISTWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Cash flow contributes 8/10 to the score.
- Quality contributes 12/20 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -317.3%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 97th percentile of the scored universe and 95th percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter pledge is zero.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 95th pctile, median 70 · Large: 89th pctile, median 74
66 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 2.1%.
- ▸10 years of positive FCF.
- ▸Debt/equity is 0.10.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 34.80
- P/B
- 5.19
- EV/EBITDA
- 19.84
- Market Cap
- 41817.00Cr
Profitability
- ROE
- 16.00%
- ROCE
- 17.30%
- ROA
- 9.57%
- Dividend Y
- 0.24%
Growth (CAGR)
- Revenue 5Y
- 12.00%
- EPS 5Y
- 1.00%
- Revenue 3Y
- 16.00%
- EPS 3Y
- 38.00%
Balance Sheet
- Debt/Equity
- 0.10
- Interest Coverage
- 22.78×
- Altman Z
- 8.21
- Book Value
- 318.00
Cash Flow
- FCF Yield
- 2.14%
- FCF Positive Y
- 10/5
- OCF
- 1142.00 Cr
- EPS TTM
- 44.98
Shareholding
- Promoter Hold
- 44.72%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 93%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.